LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 22

Search options

  1. Article: Einführung einer umfassenden Leistungserfassung in der Psychiatrie. Erste Erfahrungen an der Klinik Hohe Mark

    Bachner, Ulrike / Grabe, Martin / Haselhorst, Gerd

    KU-Gesundheitsmanagement

    2012  Volume 81, Issue 6, Page(s) 23

    Language German
    Document type Article
    ZDB-ID 2420760-3
    ISSN 1867-9269 ; 0023-4508
    Database Current Contents Medicine

    More links

    Kategorien

  2. Book ; Online: Sponsoring im internationalen Profi-Fußball

    Bachner, Michael

    2012  

    Abstract: ... von Automobilherstellern genutzt, um in einem positiven Umfeld bzw. auf der Plattform Fußball ihre Marke zu präsentieren ...

    Abstract Die FIFA Fussball Weltmeisterschaft 2006 in Deutschland wurde nach Angaben der FIFA weltweit in 214 Ländern übertragen. Insgesamt verfolgten dieses sportliche Großereignis über 26 Milliarden Zuschauer vor dem Fernseher. Diese unglaublich große Begeisterung und Faszination für den Fußball wird zunehmend von Automobilherstellern genutzt, um in einem positiven Umfeld bzw. auf der Plattform Fußball ihre Marke zu präsentieren. Sportsponsoring stellt dabei im Rahmen einer erlebnisorientierten Markenführung für einen Automobilhersteller ein sehr gutes Kommunikationsinstrument dar. Neben dem reinen fu
    Keywords Wirtschaft Marketing / Verkauf
    Language German
    Size Online-Ressource (105 p)
    Publisher Diplomica Verlag
    Publishing place Hamburg
    Document type Book ; Online
    Note Description based upon print version of record
    ISBN 9783842884960 ; 3842884966
    Database Library catalogue of the German National Library of Science and Technology (TIB), Hannover

    More links

    Kategorien

  3. Article: Vinflunine in the treatment of bladder cancer.

    Bachner, Mark / De Santis, Maria

    Therapeutics and clinical risk management

    2009  Volume 4, Issue 6, Page(s) 1243–1253

    Abstract: Vinflunine (VFL) is a third-generation bifluorinated semi-synthetic vinca alkaloid obtained by superacidic chemistry from its parent compound, vinorelbine. As with the other vinca alkaloids, the main antineoplastic effects of VFL arise from its ... ...

    Abstract Vinflunine (VFL) is a third-generation bifluorinated semi-synthetic vinca alkaloid obtained by superacidic chemistry from its parent compound, vinorelbine. As with the other vinca alkaloids, the main antineoplastic effects of VFL arise from its interaction with tubulin, the major component of microtubules in mitotic spindles. In contrast to other vinca alkaloids, VFL shows some distinctive properties in terms of tubulin binding, possibly explaining its superior antitumor activity in vitro and in vivo compared with vinorelbine as well as its excellent safety profile. In transitional cell carcinoma (TCC), two single-agent phase II trials were performed testing VFL in platinum-pretreated patients, showing moderate response rates and promising disease control rates. Therefore, the first phase III trial in modern times for second-line TCC of the urothelium was designed in order to further investigate the activity of VFL. First results were presented at the 2008 ASCO conference. VFL appears to be a possible treatment option for patients with TCC progressing after first-line platinum-containing chemotherapy.
    Language English
    Publishing date 2009-01-06
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2186560-7
    ISSN 1178-203X ; 1176-6336
    ISSN (online) 1178-203X
    ISSN 1176-6336
    DOI 10.2147/tcrm.s3384
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Second-line therapy in bladder cancer.

    Bachner, Mark / De Santis, Maria

    Current opinion in urology

    2009  Volume 19, Issue 5, Page(s) 533–539

    Abstract: Purpose of review: To review new developments in second-line treatment for transitional cell carcinoma of the urinary bladder focusing on advances and findings within the last year.: Recent findings: So far no standard therapy has been established ... ...

    Abstract Purpose of review: To review new developments in second-line treatment for transitional cell carcinoma of the urinary bladder focusing on advances and findings within the last year.
    Recent findings: So far no standard therapy has been established for pretreated patients with transitional cell carcinoma. Prognostic and predictive factors for response and outcome in pretreated patients have been studied retrospectively and will help to identify those who might benefit from intensive therapy and those who would rather improve their quality of life with best supportive care. Single-agent chemotherapy in this setting provided low response rates, short progression-free and overall survival. Vinflunine, a novel vinca-alkaloid, and best supportive care had a modest, but still significant benefit at a very moderate toxicity rate in a randomized phase III trial. As for second-line combination chemotherapy, response rates as well as potential toxicities are higher and the progression-free survival and overall survival benefits are still poorly understood. New chemotherapeutics and approaches like metronomic chemotherapy and novel agents are under investigation.
    Summary: With vinflunine there is reasonable hope for a new standard chemotherapy in second-line management of transitional cell carcinoma. However, due to the reported results with single agents and combination chemotherapy, treatment within clinical trials is still the best choice in patients progressing after first-line chemotherapy.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/drug therapy ; Drug Therapy, Combination ; Folic Acid Antagonists/therapeutic use ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Salvage Therapy ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/drug therapy ; Vinblastine/analogs & derivatives ; Vinblastine/therapeutic use
    Chemical Substances Antineoplastic Agents ; Folic Acid Antagonists ; vinflunine (5BF646324K) ; Vinblastine (5V9KLZ54CY)
    Language English
    Publishing date 2009-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0b013e32832eb473
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.

    De Santis, Maria / Bachner, Mark

    Current opinion in urology

    2007  Volume 17, Issue 5, Page(s) 363–368

    Abstract: Purpose of review: To review the systemic treatment, patient selection and treatment outcome of transitional cell carcinoma of the urinary bladder, squamous cell carcinoma and adenocarcinoma, focusing on advances and findings within the last year.: ... ...

    Abstract Purpose of review: To review the systemic treatment, patient selection and treatment outcome of transitional cell carcinoma of the urinary bladder, squamous cell carcinoma and adenocarcinoma, focusing on advances and findings within the last year.
    Recent findings: Cisplatin-based chemotherapy is considered to be the standard treatment for transitional cell carcinoma. In recent updates of randomized trials, patients with favorable prognostic factors were shown to have a chance of long-term disease-free survival even after chemotherapy for metastatic disease. Patient selection for cisplatin, newer drugs or alternative combinations is crucial. New genetic markers like excision repair cross-complementing 1 expression were developed and tested for this purpose. Adequate evaluation of renal function plays an important role for treatment selection, especially in the elderly population. Newer chemotherapeutics like oxaliplatin, vinflunine and pemetrexed have been studied in the first- or second-line settings. Their efficacy is promising, but there is still a need for further testing. Only few data are available on the systemic treatment of squamous cell carcinoma and adenocarcinoma. Complete resection seems to be more important than chemotherapy in the rare cases of adenocarcinoma of the urinary tract.
    Summary: In locally advanced and metastatic disease patient- and tumor-related prognostic factors and predictive factors for response to treatment will guide treatment decisions in the future.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Age Factors ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/mortality ; Carcinoma, Transitional Cell/pathology ; Chemotherapy, Adjuvant ; Cisplatin/administration & dosage ; Humans ; Neoplasm Metastasis ; Patient Selection ; Treatment Outcome ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/mortality ; Urinary Bladder Neoplasms/pathology
    Chemical Substances Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2007-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1091792-5
    ISSN 1473-6586 ; 0963-0643
    ISSN (online) 1473-6586
    ISSN 0963-0643
    DOI 10.1097/MOU.0b013e3282c4b0cb
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Vinflunine in the treatment of bladder cancer

    Mark Bachner / Maria De Santis

    Therapeutics and Clinical Risk Management, Vol 2008, Iss Issue 6, Pp 1243-

    2008  Volume 1253

    Abstract: Mark Bachner, Maria De Santis3rd Medical Department – Center for Oncology and Hematology, Kaiser ...

    Abstract Mark Bachner, Maria De Santis3rd Medical Department – Center for Oncology and Hematology, Kaiser Franz Josef-Spital der Stadt Wien, and Ludwig Boltzmann-Institute for Applied Cancer Research Vienna (LBI-ACR VIEnna), Cluster Translational Oncology, Kaiser Franz Josef-Spital der Stadt Wien, and Applied Cancer Research – Institution for Translational Research Vienna (ACR-ITR VIEnna)/CEADDP, Vienna, AustriaAbstract: Vinflunine (VFL) is a third-generation bifluorinated semi-synthetic vinca alkaloid obtained by superacidic chemistry from its parent compound, vinorelbine. As with the other vinca alkaloids, the main antineoplastic effects of VFL arise from its interaction with tubulin, the major component of microtubules in mitotic spindles. In contrast to other vinca alkaloids, VFL shows some distinctive properties in terms of tubulin binding, possibly explaining its superior antitumor activity in vitro and in vivo compared with vinorelbine as well as its excellent safety profile. In transitional cell carcinoma (TCC), two single-agent phase II trials were performed testing VFL in platinum-pretreated patients, showing moderate response rates and promising disease control rates. Therefore, the first phase III trial in modern times for second-line TCC of the urothelium was designed in order to further investigate the activity of VFL. First results were presented at the 2008 ASCO conference. VFL appears to be a possible treatment option for patients with TCC progressing after first-line platinum-containing chemotherapy.Keywords: vinflunine, transitional cell carcinoma (TCC) of the bladder, bladder cancer, chemotherapy, second-line chemotherapy
    Keywords Pharmacy and materia medica ; RS1-441 ; Medicine ; R ; DOAJ:Pharmacy and materia medica ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 610
    Language English
    Publishing date 2008-11-01T00:00:00Z
    Publisher Dove Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: The polycyclic Lausche Volcano (Lausitz Volcanic Field) and its message concerning landscape evolution in the Lausitz Mountains (northern Bohemian Massif, Central Europe)

    Wenger, Erik / Jörg Büchner / Jan Mrlina / Olaf Tietz

    Geomorphology. 2017,

    2017  

    Abstract: ... environs. The remnant of an alluvial fan marking a Middle Paleocene–Lower Eocene palaeo-surface is ...

    Abstract The Tertiary Lausitz Volcanic Field covers a broad area encompassing parts of Eastern Saxony (Germany), Lower Silesia (Poland) and North Bohemia (Czech Republic). Volcanism was predominantly controlled by the volcano-tectonic evolution of the Ohře Rift and culminated in the Lower Oligocene. This paper deals with the highest volcano of this area, the Lausche Hill (792.6m a.s.l.) situated in the Lausitz Mountains. We offer a reconstruction of the volcanic edifice and its eruptive history. Its complex genesis is reflected by six different eruption styles and an associated petrographic variety. Furthermore, the Lausche Volcano provides valuable information concerning the morphological evolution of its broader environs. The remnant of an alluvial fan marking a Middle Paleocene–Lower Eocene palaeo-surface is preserved at the base of the volcano. The deposition of this fan can be attributed to a period of erosion of its nearby source area, the Lausitz Block that has undergone intermittent uplift at the Lausitz Overthrust since the Upper Cretaceous. The Lausche Hill is one of at least six volcanoes in the Lausitz Mountains which show an eminent low level of erosion despite their Oligocene age and position on elevated terrain. These volcanoes are exposed in their superficial level which clearly contradicts their former interpretation as subvolcanoes. Among further indications, this implies that the final morphotectonic uplift of the Lausitz Mountains started in the upper Lower Pleistocene due to revived subsidence of the nearby Zittau Basin. The formation of the low mountain range was substantially controlled by the intersection of the Lausitz Overthrust and the Ohře Rift.
    Keywords basins ; landscapes ; mountains ; subsidence ; volcanic activity ; volcanoes ; Central European region ; Czech Republic ; Germany ; Poland
    Language English
    Size p. .
    Publishing place Elsevier B.V.
    Document type Article
    Note Pre-press version
    ZDB-ID 58028-4
    ISSN 0169-555X
    ISSN 0169-555X
    DOI 10.1016/j.geomorph.2017.04.021
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  8. Article ; Online: Organisation, Administration und Durchfuhrung von klinischen Studien.

    Bachner, Mark / Steininger, Tanja / Gneist, Margit

    Onkologie

    2008  Volume 31 Suppl 2, Page(s) 3–6

    Abstract: This contribution deals with all important organizational and administrative aspects of clinical studies in German speaking countries. All trials are to be executed in accordance with the Good Clinical Practice (GCP) Guidelines. GCP applies to the ... ...

    Title translation Organization, administration, and performance of clinical studies.
    Abstract This contribution deals with all important organizational and administrative aspects of clinical studies in German speaking countries. All trials are to be executed in accordance with the Good Clinical Practice (GCP) Guidelines. GCP applies to the process of designing, conducting, recording, and reporting of clinical studies. Compliance with GCP facilitates the mutual acceptance of resulting clinical data by the respective regulatory authorities worldwide. Before initiating a clinical study the investigator has to obtain written and dated approval from the responsible ethics committee, the competent authorities, and the hospital administration. The investigator's study file contains all essential study documents. One of the most important tasks of an investigator is to properly inform the prospective subjects and to obtain their informed consent. All relevant treatment-related information has to be recorded in the patient files. These source data are transferred to case report forms. During monitoring visits, audits, and inspections, source data verification will be performed routinely. Any adverse events (AEs) must be documented according to the CTCAE, the Common Terminology Criteria for Adverse Events. All serious adverse events (SAEs) have to be reported to the sponsor immediately. At the end of the study a termination visit is performed, and all authorities are officially informed about the termination of the trial.
    MeSH term(s) Clinical Trials as Topic/methods ; Clinical Trials as Topic/standards ; Germany ; Guideline Adherence/organization & administration ; Informed Consent/standards ; Practice Guidelines as Topic ; Research/organization & administration ; Research Design
    Language German
    Publishing date 2008
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 549601-9
    ISSN 1423-0240 ; 0378-584X
    ISSN (online) 1423-0240
    ISSN 0378-584X
    DOI 10.1159/000113030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Quality improvement in the modern clinical laboratory: the regulatory and accreditation perspective.

    Bachner, P

    Disease markers

    1992  Volume 10, Issue 1, Page(s) 27–35

    MeSH term(s) Accreditation ; Humans ; Laboratories/standards ; Quality Control ; United States
    Language English
    Publishing date 1992-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604951-5
    ISSN 1875-8630 ; 0278-0240
    ISSN (online) 1875-8630
    ISSN 0278-0240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Physical therapy students' willingness to report misconduct to protect the patient's interests.

    Mansbach, Abraham / Bachner, Yaacov G / Melzer, Itzik

    Journal of medical ethics

    2010  Volume 36, Issue 12, Page(s) 802–805

    Abstract: ... than externally. The pattern reveals a desire to correct the misconduct coupled with a marked decline ...

    Abstract This article presents a study on the ethical dilemma of whistleblowing in physical therapy, and suggests some lines for further research on this topic as well as ways for integrating it in the physical therapy curriculum. The study examines the self-reported willingness of physical therapy students to report misconduct, whether internally or externally, to protect the patient's interests. Internal disclosure entails reporting the wrongdoing to an authority within the organisation. External disclosure entails reporting the offence to an outside agency, such as the police, professional organisation, or press. The findings indicate that the students view the acts that are detrimental or cause injustice to the patient in a very serious light. In dilemma situations such as these, the students reported a willingness to act. The students also report considerably greater likelihood of whistleblowing internally than externally. The pattern reveals a desire to correct the misconduct coupled with a marked decline in the willingness to blow the whistle as this act moved from the workplace to an external authority.
    MeSH term(s) Adult ; Attitude of Health Personnel ; Female ; Humans ; Interpersonal Relations ; Male ; Patient Rights ; Physical Therapy Modalities/ethics ; Professional Misconduct ; Students, Medical/psychology ; Surveys and Questionnaires ; Whistleblowing/ethics ; Workplace ; Young Adult
    Language English
    Publishing date 2010-12
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 194927-5
    ISSN 1473-4257 ; 0306-6800
    ISSN (online) 1473-4257
    ISSN 0306-6800
    DOI 10.1136/jme.2010.036046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top